Verve Therapeutics Inc.

Products

Category

Product

Brand

Description

Genome Editing (BIO146D)

Verve-102		Verve-102 targets the same PCSK9 gene as Verve-101 but uses Verve’s proprietary GalNAc-LNP delivery system for improved liver targeting and potentially better safety. It is currently being evaluated in the Heart-2 Phase 1b clinical trial for patients with HeFH and premature coronary artery disease.
Verve-201		Verve-201 aims to inactivate the ANGPTL3 gene in the liver to lower both LDL-C and triglyceride levels. It is being developed for patients with homozygous familial hypercholesterolemia (HoFH) and those with refractory hypercholesterolemia who do not achieve target LDL-C levels despite standard therapies.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment